Voyager Therapeutics, Inc. (VYGR)
1.62
+0.01
(+0.62%)
USD |
NASDAQ |
Nov 20, 09:49
Voyager Therapeutics Free Cash Flow : -109.83M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -109.83M |
| June 30, 2026 | -121.42M |
| March 31, 2026 | -129.94M |
| December 31, 2025 | -135.06M |
| September 30, 2025 | -118.86M |
| June 30, 2025 | -115.83M |
| March 31, 2025 | -114.01M |
| December 31, 2024 | -18.83M |
| September 30, 2024 | -28.66M |
| June 30, 2024 | -22.27M |
| March 31, 2024 | 8.233M |
| December 31, 2023 | 74.66M |
| September 30, 2023 | 86.00M |
| June 30, 2023 | 91.35M |
| March 31, 2023 | 73.67M |
| December 31, 2022 | -15.00M |
| September 30, 2022 | 9.025M |
| June 30, 2022 | 4.139M |
| March 31, 2022 | 0.923M |
| December 31, 2021 | -55.13M |
| September 30, 2021 | -91.52M |
| June 30, 2021 | -100.04M |
| Date | Value |
|---|---|
| March 31, 2021 | -100.18M |
| December 31, 2020 | -108.81M |
| September 30, 2020 | -110.02M |
| June 30, 2020 | -102.88M |
| March 31, 2020 | -113.42M |
| December 31, 2019 | 40.95M |
| September 30, 2019 | 42.81M |
| June 30, 2019 | 47.07M |
| March 31, 2019 | 56.86M |
| December 31, 2018 | -20.19M |
| September 30, 2018 | -10.32M |
| June 30, 2018 | -8.119M |
| March 31, 2018 | -1.093M |
| December 31, 2017 | -65.34M |
| September 30, 2017 | -67.30M |
| June 30, 2017 | -61.69M |
| March 31, 2017 | -54.80M |
| December 31, 2016 | -47.51M |
| September 30, 2016 | -40.23M |
| June 30, 2016 | -36.54M |
| March 31, 2016 | -34.12M |
| December 31, 2015 | 40.27M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Lineage Cell Therapeutics, Inc. | -26.46M |
| Armata Pharmaceuticals, Inc. | -26.86M |
| Black Diamond Therapeutics, Inc. | -33.32M |
| Invivyd, Inc. | -134.11M |
| Elicio Therapeutics, Inc. | -36.99M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -19.67M |
| Cash from Investing (Quarterly) | 29.27M |
| Cash from Financing (Quarterly) | 3.033M |
| Free Cash Flow Per Share (Quarterly) | -0.3181 |
| Free Cash Flow to Equity (Quarterly) | -17.61M |
| Free Cash Flow to Firm (Quarterly) | -19.67M |
| Free Cash Flow Yield | -109.0% |